|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Manuela Velázquez Prieto
EDITOR IN CHIEF
Jaime E. Poquet Jornet
Tomás Casasín Edo
Virginia Hernández Corredoira
Ramón Jódar Masanés
Juan Carlos Juárez Giménez
Volume 20 - Issue 1, January-February 2018
DRUG COST AVOIDANCE RESULTING FROM BREAST CANCER CLINICAL TRIALS
MAÑES SEVILLA MIREYA, ROMERO JIMÉNEZ ROSA, HERRANZ ALONSO ANA, SÁNCHEZ FRESNEDA MARÍA NORBERTA, GONZÁLEZ HABA EVA, COLLADO BORRELL ROBERTO, GARCÍA GONZÁLEZ XANDRA, BENEDI GONZÁLEZ JUANA, SANJURJO SÁEZ MARÍA
Background: Adequately quantifying cost savings associated with clinical trials (CT) is fundamental to manage research in a proactive manner. The objectives of this study were to determine if CT for the treatment of breast cancer with pharmacy managed ensuring Investigational Medicinal Products (IMP) were associated with direct cost savings and to quantify these cost savings.
Method: Observational, retrospective study. Inclusion criteria: breast cancer patients that enrolled in a CT with IMP managed by the pharmacy. Direct cost savings were calculated as the avoided drug expenses that result
when a patient enrolls in a CT and receives an IMP that is provided by the sponsor, hence sparing the hospital of the cost of the standard treatment.
Results: Thirty seven CT with a total of eighty nine breast cancer patients were included in the study. They provided an economic saving, on avoided cost in drug, of €957,246 in the period of the three years. On average, every patient that enrolled in a CT with sponsor provided IMP saved €10,756.
Conclusions: Our study suggests that those CT in which anti-neoplastic agents are provided or refunded by the sponsor provide substantial cost savings.
BREAST CANCER – CLINICAL TRIAL – COST SAVINGS – COST AVOIDANCE –
INVESTIGATIONAL MEDICINAL PRODUCTS